



PRACTICAL METHODS FOR  
**BIOCATALYSIS AND  
BIOTRANSFORMATIONS 2**



Editors JOHN WHITTALL | PETER W. SUTTON

 **WILEY**



# Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[List of Contributors](#)

[Abbreviations](#)

[Chapter 1: Biocatalysis in the Fine Chemical and Pharmaceutical Industries](#)

[1.1 Introduction](#)

[1.2 Biotrans Outsourcing – AstraZeneca](#)

[1.3 Biotrans Trends – Lonza](#)

[1.3.1 Downstream Processing – Lonza](#)

[1.4 Biocatalysis in the Pharma Environment](#)

[1.4.1 Value Creation by Biocatalysis – Roche](#)

[1.4.2 Discovery Chemistry and Manufacturing in Pharma – Pfizer](#)

[1.4.3 Drug Metabolites and Building Blocks – Novartis](#)

[1.4.4 Biotrans Using Isolated Enzymes – Merck](#)

[1.5 Industrial Use of Hydrolases](#)

[1.5.1  \$\beta\$ -Lactam Antibiotics Synthesis – GSK](#)

[1.5.2 Preparative Use of Phosphatases and Transglycosylases – LibraGen](#)

[1.5.3 Biocatalytic Desymmetrization and Dynamic Kinetic Resolution \(DKR\) Processes – AstraZeneca](#)

## 1.6 Industrial Biooxidation and Reduction

1.6.1 Approaches to Chiral Secondary Alcohols - Dr Reddy's, Chirotech

1.6.2 Application of Alcohol Dehydrogenases and P450 Oxidation - Almac

## 1.7 Industrial Application of Transaminases - Cambrex

## 1.8 Biocatalyst Discovery and Improvement

1.8.1 Directed Evolution Technologies - Codexis

1.8.2 Discovering Novel Enzymes from Untapped Biodiversity - LibraGen

## 1.9 From Pathway Engineering to Synthetic Biology

1.9.1 Pathway Engineering in Yeast - Sanofi

1.9.2 Application of Synthetic Biology - Ingenza

## 1.10 Prioritization of Future Biocatalysis and Synthetic Biology Needs

## 1.11 Concluding Remarks

Acknowledgements

References

# Chapter 2: Reductive Amination

## 2.1 $\omega$ -Transaminases - Useful Biocatalysts for Chiral Amine Synthesis

2.1.1 Chiral Amine Synthesis

Acknowledgements

References

## 2.2 Preparative Scale Production of a Bulky-Bulky Chiral Amine Using an Engineered Transaminase

2.2.1 Kilogram Scale Procedure

2.2.2 Conclusions

References

## 2.3 Synthesis of Optically Pure Amines Employing $\omega$ -Transaminases

### 2.3.1 Procedure 1: Kinetic Resolution

### 2.3.2 Procedure 2: Asymmetric Reductive Amination Employing System 1

### 2.3.3 Procedure 3: Asymmetric Reductive Amination Employing System 2

### 2.3.4 Conclusion

### References

## 2.4 A Fast, Sensitive Assay and Scale-Up of $\omega$ -Transaminase Catalysed Reactions

### 2.4.1 Procedure 1: A Fast and Sensitive Assay for Measuring the Activity and Enantioselectivity of Transaminases

### 2.4.2 Procedure 2: Scale Up of a TA-Catalysed Preparation of (R)- $\alpha$ -Methylbenzylamine

### 2.4.3 Analytical

### 2.4.4 Conclusion

### References

## 2.5 Asymmetric Synthesis of 1-3-Hydroxyadamantylglycine Using Branched Chain Aminotransferase

### 2.5.1 Procedure: Preparation of 1-3-Hydroxyadamantylglycine(2-(3-Hydroxy-1-Adamantyl)-(2S)-Amino Ethanoic Acid) (L-HAG)

### 2.5.2 Conclusion

### References

## 2.6 Asymmetric Reduction of Aryl Imines Using *Candida parapsilosis* ATCC 7330

### 2.6.1 Procedure 1: Asymmetric Reduction of (E)-N-(1-Phenylethylidene)Benzenamine 1a using Whole Cells of *Candida parapsilosis* ATCC 7330

### 2.6.2 Spectral Data for Compounds 2b, 5b and 6b

[2.6.3 Conclusion](#)  
[References](#)

## [Chapter 3: Enoate Reductases for Reduction of Electron Deficient Alkenes](#)

### [3.1 Asymmetric Bioreduction of Activated Alkenes Using Ene-Reductases from the Old Yellow Enzyme Family](#)

[3.1.1 Procedure 1: Organic Solvent Effect in the Asymmetric Synthesis of the Olfactory Compounds Lysmeral™ and Helional™](#)<sup>7</sup>

[3.1.2 Procedure 2: Protecting Group Effect in the Asymmetric Synthesis of the Chiral Pharmaceutical Building Block 'Roche Ester'](#)<sup>10</sup>

[3.1.3 Procedure 3: Cofactor Regeneration System Effect in the Asymmetric Synthesis of \(6R\)-Levodione, a Precursor of Actinol](#)<sup>8,13</sup>

[3.1.4 Procedure 4: Substrate Structure/Stereochemistry and Enzyme Effects in the Asymmetric Synthesis of Dicarboxylic Acid Esters](#)<sup>9</sup>  
[References](#)

### [3.2 Efficient Baker's Yeast Mediated Reduction with Substrate Feeding Product Removal \(SFPR\) Technology: Synthesis of \(S\)-2-Alkoxy-3-Aryl-1-Propanols](#)

[3.2.1 Baker's Yeast Mediated Synthesis of \(S\)-2-Alkoxy-3-\(4-Methoxyphenyl\)-1-Propanols](#)

[3.2.2 Conclusion](#)

[References and Notes](#)

### [3.3 Asymmetric Reduction of \(4S\)-\(+\)-Carvone Catalyzed by Enoate Reductases \(ERs\) Expressed](#)

## by Non-Conventional Yeast (NCY) Whole Cells

### 3.3.1 Materials and Equipment

### 3.3.2 Procedure

### References and Notes

## 3.4 Preparation of Enantiomerically Pure Citronellal Enantiomers Using Alkene Reductases

### 3.4.1 Materials and Equipment

### 3.4.2 Procedure

### 3.4.3 Analytical Methods

### 3.4.4 Conclusion

### References and Notes

## 3.5 Highly Enantiomeric Hydrogenation of C-C Double Bond of Methylated N-Phenyl and N-Phenylalkylmaleimides by Aspergillus fumigatus

### 3.5.1 Biocatalytic Synthesis of Enantiomeric Pure 2-Methyl- and 2,3-Dimethyl-N-Phenyl and N-Phenylalkyl Succinimides

### 3.5.2 Product Analysis

### 3.5.3 Conclusion

## Chapter 4: Industrial Carbonyl Reduction

### 4.1 Bioreduction Using Immobilized Carbonyl Reductase Technology

#### 4.1.1 Materials and Equipment

#### 4.1.2 Procedure

#### 4.1.3 Conclusion

#### References

### 4.2 Preparative Ketoreductase-Catalyzed Kinetic Resolution of a Racemic Aldehyde

#### 4.2.1 2 L Scale Procedure

#### 4.2.2 Conclusions

#### References

### 4.3 Enzymatic Reduction of 2,6-dichloro-3-fluoroacetophenone to Produce (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol

4.3.1 Procedure: Preparation of (1s)-1-(2,6-dichloro-3-fluorophenyl)ethanol (2)

4.3.2 Conclusion

References and Notes

### 4.4 Preparative Scale Production of Poorly Soluble Chiral Alcohol Intermediate for Montelukast

4.4.1 1-L Scale Procedure

4.4.2 Conclusions

References

## Chapter 5: Regio- and Stereoselective Hydroxylation

### 5.1 Engineering of an Amycolatopsis orientalis P450 Compactin Hydroxylase into a Pravastatin Synthase by Changing the Stereospecificity of the Enzyme

5.1.1 General Materials and Strains

5.1.2 Procedure 1: Generation of an Error Prone Library of Amycolatopsis orientalis P450 Hydroxylase

5.1.3 Procedure 2: Screening of the Error Prone Library for Improved Pravastatin: epi-Pravastatin Conversion Ratio

5.1.4 Procedure 3: Construction and Screening of the Second Generation Library Consisting of Site Saturation and Shuffling Approaches

5.1.5 Conclusion

References

### 5.2 Recombinant Human Cytochrome P450 Enzymes Expressed in Escherichia coli as Whole

## Cell Biocatalysts: Preparative Synthesis of Oxidized Metabolites of an mGlu5 Receptor Antagonist

5.2.1 Procedure 1: Screening of 14 rec. h. CYP-Isoforms for Biocatalyst Selection

5.2.2 Procedure 2: Propagation of E. coli JM109 Expressing rec. h. CYP3A4 and rec. h. P450 Reductase and Preparation of a Cell Suspension (Biocatalyst Production)

5.2.3 Procedure 3: Biotransformation with E. coli JM109 Expressing rec. h. CYP3A4 plus rec. h. P450 Reductase and Metabolite Purification

5.2.4 Conclusion

References and Notes

## 5.3 Alpha-Keto Biooxidation Using Cunninghamella echinulata (DSM 63356)

5.3.1 Materials and Equipment

5.3.2 Procedure

5.3.3 Conclusion

References

## 5.4 Aromatic Hydroxylation: Preparation of 3,4-Dihydroxyphenylacetic Acid

5.4.1 Preparation of 3,4-Dihydroxyphenylacetic Acid

5.4.2 Analytical Methods

5.4.3 Conclusion

Reference and Note

## 5.5 Regioselective Aromatic Hydroxylation of Quinaldine Using Living Pseudomonas putida Cells Containing Quinaldine 4-Oxidase

5.5.1 Biocatalytic Hydroxylation of Quinaldine by Quinaldine 4-Oxidase

5.5.2 Analytical Methods

5.5.3 Product Isolation

[5.5.4 Conclusion](#)

[References](#)

[5.6 Regioselective Preparation of 5-Hydroxypropranolol with a Fungal Peroxygenase](#)

[5.6.1 Materials and Equipment](#)

[5.6.2 Procedure](#)

[5.6.3 Conclusion](#)

[References](#)

[5.7 Microbial Conversion of  \$\beta\$ -Myrcene to Geraniol by a Strain of Rhodococcus](#)

[5.7.1 Procedure 1: Growth of the Bacterium](#)

[Rhodococcus erythropolis NCIMB 14574 on  \$\beta\$ -Myrcene](#)

[5.7.2 Procedure 2: Biotransformation of  \$\beta\$ -Myrcene to Geraniol by Rhodococcus erythropolis NCIMB 14574](#)

[5.7.3 Analysis](#)

[5.7.4 Conclusion](#)

[References and Notes](#)

## [Chapter 6: Oxidation of Alcohols](#)

[6.1 Preparative Method for the Enzymatic Synthesis of 5-Ketogluconic Acid and its Isolation](#)

[6.1.1 Procedure for the Preparation of 5-KGA](#)

[6.1.2 Conclusion](#)

[References](#)

[6.2 Selective Enzymatic Oxidation of Atropisomeric Diaryl Ethers by Oxidation with Oxygen and Catalytic Galactose Oxidase M<sub>3-5</sub>](#)

[6.2.1 Procedure: Enzymatic Desymmetrization of an Atropisomeric Diaryl Ether](#)

[6.2.2 Conclusion](#)

[References](#)

## 6.3 Kinetic Resolution of Chiral Secondary Alcohols by Oxidation with Oxygen and Catalytic Galactose Oxidase M<sub>3-5</sub>

6.3.1 Procedure 1: Preparation of Galactose Oxidase (GOase) and Purification

6.3.2 Procedure 2: Enzymatic Kinetic Resolution of Chiral Secondary Alcohols<sup>1</sup>

6.3.3 Conclusion

Reference

## 6.4 ADH Catalyzed Oxidation of Sec-Alcohols Using Molecular Oxygen

6.4.1 Materials and Equipment

6.4.2 Procedure

6.4.3 Conclusion

References

## 6.5 Irreversible Non-Enantioselective Oxidation of Secondary Alcohols Using *Sphingobium* ADH and Chloroacetone as Oxidant

6.5.1 Materials and Equipment

6.5.2 Procedure

6.5.3 Conclusion

References

## 6.6 Chemoselective Oxidation of Primary Alcohols to Aldehydes

6.6.1 Materials and Equipment

6.6.2 Procedure

6.6.3 Analytics

6.6.4 Conclusion

References

# Chapter 7: Selective Oxidation

## 7.1 Enantioselective Biocatalytic Oxidative Desymmetrization of Substituted Pyrrolidines

7.1.1 Procedure 1: Preparation of the Biocatalyst

7.1.2 Procedure 2: Desymmetrization of Pyrrolidines

7.1.3 Procedure 3: Stereoselective Synthesis of the Amino Acid

7.1.4 Conclusion

References

## 7.2 Large Scale Baeyer-Villiger Monooxygenase-Catalyzed Conversion of (R,S)-3-phenylbutan-2-one

7.2.1 Procedure 1: Recombinant Expression of the Baeyer-Villiger Monooxygenase from *Pseudomonas putida* JD1 in *Escherichia coli*

7.2.2 Procedure 2: Biocatalytic Conversion of (R,S)-3-Phenylbutan-2-one

7.2.3 Conclusion

References

## 7.3 Synthesis of Optically Active 3-Alkyl-3-,4-dihydroisocoumarins by Dynamic Kinetic Resolutions Catalyzed by a Baeyer-Villiger Monooxygenase

7.3.1 Procedure: Dynamic Kinetic Resolution using M446G PAMO Cell Free Extract

7.3.2 Conclusion

References

## 7.4 Oxidative Cleavage of the B-Ring of (+)-Catechin

7.4.1 Procedure: Biocatalytic Conversion of (+)-Catechin (1) to Novel B-Ring Fission Lactones (2, 3)

7.4.2 Conclusion

References

## 7.5 $^{18}\text{O}$ -Isotopic Labeling in the Meta-Dioxygenase Cleavage of (+)-Catechin B-Ring

### 7.5.1 Proposed Pathway for the Conversion of (+)-Catechin (1) to $^{18}\text{O}$ -Labeled, Novel B-Ring Fission Lactones (2, 3)

### 7.5.2 $\text{H}_2$ $^{18}\text{O}$ and $^{18}\text{O}_2$ Labeling Experiments

### 7.5.3 Conclusion

### References

## 7.6 Biocatalytic Cleavage of Alkenes with Oxygen and *Trametes hirsuta* G FCC047

### 7.6.1 Procedure 1: Analytical Scale

### 7.6.2 Procedure 2: Preparative Scale

### 7.6.3 Conclusion

### References

# Chapter 8: Industrial Hydrolases and Related Enzymes

## 8.1 Dynamic Kinetic Resolution of $\alpha$ -Halo Esters with Hydrolytic Enzymes and Sec-amine Bases

### 8.1.1 Materials and Equipment

### 8.1.2 Procedures

### 8.1.3 Analytical Methods used for $\alpha$ -Chloroesters and Acids

### 8.1.4 Conclusion

### Reference

## 8.2 Kinetic Resolution of an Amino Ester Using Supported *Mucor miehei* Lipase (Lipozyme<sup>®</sup> RM IM)

### 8.2.1 Procedure 1: Resolution of Ester III

### 8.2.2 Procedure 2: Resolution of Ester I

### 8.2.3 Procedure 3: Recycling of (S)-Acid

### 8.2.4 Conclusion

[Reference](#)

[8.3 Large Scale Synthesis of \(S\)-Allysine Ethylene Acetal via Amino Acylase Resolution](#)

[8.3.1 Materials](#)

[8.3.2 Procedure](#)

[8.3.3 Conclusion](#)

[References and Notes](#)

[8.4 Pilot-Scale Synthesis of \(1R,2S,4S\)-7-Oxabicyclo\[2.2.1\]heptan-2-exo-carboxylic Acid](#)

[8.4.1 Experimental](#)

[8.4.2 Conclusion](#)

[References](#)

[8.5 A Selective Lipase-Catalyzed Mono-Acetylation of a Diol Suitable for a Telescoped Synthetic Process](#)

[8.5.1 Procedure](#)

[8.5.2 Conclusion](#)

[References](#)

[8.6 A Protease-Mediated Hydrolytic Kinetic Resolution of an Atropisomeric Ester Operating Within an Unusually Narrow pH Window](#)

[8.6.1 Procedure](#)

[8.6.2 Conclusion](#)

[Reference](#)

[8.7 Asymmetric Synthesis of Quaternary Amino Acids from Simple Bis Nitriles Using a Dual Nitrile Hydratase/Amidase Biocatalyzed Reaction](#)

[8.7.1 Materials and Equipment](#)

[8.7.2 Procedures](#)

[8.7.3 Conclusion](#)

[References](#)

## 8.8 Development of an Improved Immobilized CAL-B for the Enzymatic Resolution of a Key Intermediate to Odanacatib

8.8.1 Procedure 1: CAL-B Immobilization Procedure

8.8.2 Procedure 2: Batch Reactions

8.8.3 Procedure 3: Continuous Plug Flow Reactions

8.8.4 Conclusion

References

## Chapter 9: Transferases for Alkylation, Glycosylation and Phosphorylation

### 9.1 Industrial Production of Caffeic Acid- $\alpha$ -D-O-Glucoside

9.1.1 Procedure 1: Preparation of the Glucosyltransferase Enzyme

9.1.2 Procedure 2: Preparation of Caffeic Acid- $\alpha$ -d-O-Glucoside

9.1.3 Specification of the Product

9.1.4 Analytical Controls

9.1.5 Conclusion

### 9.2 Enzymatic Synthesis of 5-Methyluridine by Transglycosylation of Guanosine and Thymine

9.2.1 Procedure 1: Production of Biocatalysts

9.2.2 Procedure 2: Biocatalytic Production of 5-Methyluridine (5-MU)<sup>9-11</sup>

9.2.3 Procedure 3: Isolation and Recovery of 5-MU

9.2.4 Conclusion

References

### 9.3 Preparation and Use of Sucrose Phosphorylase as Cross-Linked Enzyme Aggregate (CLEA)

- [9.3.1 Procedure 1: Production of Cellular Biomass](#)
- [9.3.2 Procedure 2: Cell Lysis and Enzyme Purification](#)
- [9.3.3 Procedure 3: Production of CLEAs](#)
- [9.3.4 Procedure 4: Production of  \$\alpha\$ -D-Glucose-1-phosphate](#)
- [9.3.5 Analytical Data](#)
- [9.3.6 Conclusion](#)
- [References](#)

## [9.4 Enzymatic Synthesis of Phosphorylated Carbohydrates and Alcohols](#)

- [9.4.1 Procedure: Preparative Synthesis of G6P](#)
- [9.4.2 Conclusion](#)
- [References](#)

## [9.5 Biocatalyzed Synthesis of Chiral O-Phosphorylated Derivative of 2-Hydroxy-2-phenylethanephosphonate](#)

- [9.5.1 Biotransformation of Diethyl 2-oxo-2-phenylethanephosphonate](#)
- [9.5.2 Conclusion](#)
- [References and Notes](#)

## [9.6 High Activity \$\beta\$ -Galactosidase Preparation for Diastereoselective Synthesis of \(R\)-\(1-Phenylethyl\)- \$\beta\$ -D-Galactopyranoside by Reverse Hydrolysis](#)

- [9.6.1 Introduction](#)
- [9.6.2 Conclusion](#)
- [Acknowledgements](#)
- [References](#)

## [9.7 Stereospecific Synthesis of Aszonalenins by Using Two Recombinant Prenyltransferases](#)

- [9.7.1 Procedure 1: Preparation of the Prenyltransferases CdpNPT and AnaPT](#)

[9.7.2 Procedure 2: Preparative Synthesis and Structural Elucidation of Aszonalenins](#)

[9.7.3 Conclusion](#)

[References](#)

[9.8 Enzymatic Friedel-Crafts Alkylation Catalyzed by S-Adenosyl-L-methionine Dependent Methyl Transferase](#)

[9.8.1 Procedure 1: Crotyl-S-adenosyl-L-homocysteine triflate](#)

[9.8.2 Procedure 2: N-\(8-Crotyl-4,7-dihydroxy-2-oxo-2H-chromen-3-yl\)-1H-pyrrole-2-carboxamide](#)

[9.8.3 Conclusion](#)

[References](#)

## [Chapter 10: C-C Bond Formation and Decarboxylation](#)

[10.1 Enzymatic, Stereoselective Synthesis of \(S\)-Norcoclaurine](#)

[10.1.1 Procedure 1: Synthesis of 4-Hydroxyphenylacetaldehyde](#)

[10.1.2 Procedure 2: Synthesis of \(S\)-Norcoclaurine](#)

[10.1.3 Conclusion](#)

[References](#)

[10.2 Preparation of Non-Natural Tyrosine Derivatives from Pyruvate and Phenol Derivatives](#)

[10.2.1 Procedure for the Preparation of L-3-Methoxytyrosine](#)

[10.2.3 Conclusion](#)

[References](#)

[10.3 Enzymatic  \$\alpha\$ -Decarboxylation of L-Glutamic Acid in the Production of Biobased Chemicals](#)

[10.3.1 Procedure 1: GAD Immobilization](#)

[10.3.2 Procedure 2: Product Quantification by HPLC](#)

[10.3.3 Procedure 3: GAD Activity Assay](#)

[10.3.4 Procedure 4: GAD Stability Assay](#)

[10.3.5 Conclusion](#)

[References](#)

[10.4 Asymmetric Decarboxylation of Arylmalonates and Racemization of Profens by Arylmalonate Decarboxylase and its Variants](#)

[10.4.1 Procedure 1: Asymmetric Decarboxylation of Arylmalonate](#)

[10.4.2 Procedure 2: Enzymatic Racemization of Profens](#)

[10.4.3 Conclusion](#)

[References](#)

[10.5 Improved Enzymatic Preparation of 1-Deoxy-d-xylulose 5-Phosphate](#)

[10.5.1 Synthesis of DXP](#)

[10.5.2 Purification of DXP](#)

[10.5.3 Conclusion](#)

[References](#)

[10.6 On the Use of 2-Methyltetrahydrofuran \(2-MeTHF\) as Bio-Based \(Co-\) Solvent in Biotransformations](#)

[10.6.1 The Quest for Efficient and Bio-Based \(Co-\) Solvents](#)

[10.6.2 Case Study 1: Alcohol Dehydrogenase Catalyzed Enantioselective Ketone Reduction using 2-MeTHF as \(Co-\) Solvent](#)

[10.6.3 Case Study 2: Benzaldehyde Lyase \(BAL\) Catalyzed Enantioselective C-C Bond Formation using 2-MeTHF as \(Co-\) Solvent](#)

[10.6.4 Concluding Remarks](#)

[Acknowledgements](#)

[References](#)

[10.7 The Lipase-Catalyzed Asymmetric Michael Addition of Thienyl Nitroolefin to Acetylacetone](#)

[10.7.1 Procedure 1: The Lipozyme TLIM Catalyzed Michael Addition of Thienyl Nitroolefin to Acetylacetone](#)

[10.7.2 Procedure 2: Regeneration and Reuse of Lipozyme TLIM](#)

[10.7.3 Conclusion](#)

[References](#)

[Chapter 11:  
Halogenation/Dehalogenation/Heteroatom  
Oxidation](#)

[11.1 Preparation of Halogenated Molecules by a Fungal Flavin-Dependent Halogenase Heterologously Expressed in \*Escherichia coli\*](#)

[11.1.1 Whole-Cell Biocatalytic Halogenation of Dihydroresorcyllide](#)

[11.1.2 Conclusion](#)

[References and Notes](#)

[11.2 Preparation of Optically Pure Haloalkanes and Alcohols by Kinetic Resolution Using Haloalkane Dehalogenases](#)

[11.2.1 Procedure 1: Kinetic Resolution of  \$\alpha\$ -Bromoesters and  \$\beta\$ -Bromoalkanes](#)

[11.2.2 Procedure 2: Gram-Scale Synthesis of \(S\)-2-Bromopentane](#)

[11.2.3 Conclusions](#)

[Acknowledgements](#)

[References](#)

## 11.3 Preparation of Enantiopure Sulfoxides by Enantioselective Oxidation with Whole Cells of Rhodococcus sp. ECU0066

11.3.1 Procedure: Preparation of (S)-Phenyl Methyl Sulfoxide 1a

11.3.2 Conclusion

References and Notes

## 11.4 Kinetic Resolution of an Insecticidal Dithiophosphate by Chloroperoxidase Catalyzed Oxidation of the Thiophosphoryl Group

11.4.1 Procedure: Kinetic Resolution of Racemic Dithiophosphate 1 by Oxidation with CPO/H<sub>2</sub>O<sub>2</sub> System

11.4.2 Conclusion

References

# Chapter 12: Tandem and Sequential Multi-Enzymatic Syntheses

## 12.1 Production of Isorhamnetin 3-O-Glucoside in Escherichia coli Using Engineered Glycosyltransferase

12.1.1 Materials and Equipment

12.1.2 Procedure

12.1.3 Analytical Methods

12.1.4 Conclusion

References and Notes

## 12.2 Multienzymatic Preparation of (-)-3-(Oxiran-2-yl)Benzoic Acid

12.2.1 Materials and Equipment

12.2.2 Procedure

12.2.3 Work Up Procedure

12.2.4 Analytical Methods

[12.2.5 Conclusion](#)

[References and Notes](#)

[12.3 Enzymatic Synthesis of Carbohydrates from Dihydroxyacetone and Aldehydes by a One Pot Enzyme Cascade Reaction](#)

[12.3.1 Procedure: Synthesis of 5,6-Dideoxy-D-threo-2-hexulose \(3S,4R\)](#)

[12.3.2 Conclusion](#)

[References](#)

[12.4 Aldolase Based Multi-Enzyme System for Carbon-Carbon Bond Formation](#)

[12.4.1 Procedure 1: One Pot/One Step](#)

[12.4.2 Procedure 2: One Pot/Two Steps](#)

[12.4.3 Analytical Data for the Products from Aldehyde](#)

[13](#)

[12.4.4 Conclusion](#)

[Acknowledgements](#)

[References](#)

[12.5 Tandem Biocatalytic Process for the Kinetic Resolution of  \$\beta\$ -Phenylalanine and its Analogs](#)

[12.5.1 Procedure 1: Expression and Purification of a Mutated Phenylalanine Aminomutase \(PAM-Q319M\) and Phenylalanine Ammonia Lyase \(PAL\)](#)

[12.5.2 Procedure 2: Kinetic Resolution of Racemic  \$\beta\$ -Phenylalanine](#)

[12.5.3 Conclusion](#)

[References](#)

[12.6 A Chemoenzymatic Synthesis of a Deoxy Sugar Ester of N-Boc-Protected L-Tyrosine](#)

[12.6.1 Procedure 1: The O-Alkylation of Carboxylic Acid and Lipase-Catalyzed Deacetylation \(Performed as a "One-Pot Synthesis"\)](#)

[12.6.2 Procedure 2: Lipase-Catalyzed Acetylation of Hemiacetal 3](#)

[12.6.3 Procedure 3: Lipase-Catalyzed Deacetylation of Compound 4](#)

[12.6.4 Conclusion](#)

[References](#)

[12.7 Electrochemical Systems for the Recovery of Succinic Acid from Fermentations](#)

[12.7.1 Materials and Equipment \(Fermentation\)](#)

[12.7.2 Analytical Method](#)

[12.7.3 Culture of Actinobacillus succinogenes](#)

[12.7.4 Fermentation Media](#)

[12.7.5 Fermentation](#)

[12.7.6 Work Up Electrodialysis Conditions](#)

[12.7.7 Conclusion](#)

[References and Notes](#)

[Appendix 1](#)

[Index](#)

# Practical Methods for Biocatalysis and Biotransformations 2

Edited by

JOHN WHITTALL

*Manchester Interdisciplinary Biocentre (MIB),  
The University of Manchester, UK*

PETER W. SUTTON

*GlaxoSmithKline Research and Development Limited, UK*



A John Wiley & Sons, Ltd., Publication

This edition first published 2012

© 2012 John Wiley & Sons, Ltd.

*Registered office*

John Wiley & Sons, Ltd, The Atrium, Southern Gate,  
Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com](http://www.wiley.com).

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

***Library of Congress Cataloging-in-Publication Data***

Practical methods for biocatalysis and biotransformations /  
edited by John

Whittall, Peter W. Sutton. - 2

p. cm.

Includes bibliographical references and index.

ISBN 978-1-119-99139-7 (cloth)

1. Enzymes-Biotechnology. 2. Biotransformation  
(Metabolism) 3. Organic  
compounds-Synthesis. I. Whittall, John. II. Sutton, Peter  
(Peter W.)

TP248.65.E59P73 2012

572-dc23

2012005816

# List of Contributors

**Joseph P. Adams** GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

**Joong-Hoon Ahn** Department of Bioscience and Biotechnology, Bio/Molecular Informatics Center, Konkuk University, 1 Hwayang-Dong, Gwangjin-gu, Seoul 143-701, Republic of Korea

**Ian Archer** Ingenza Limited, Joseph Black Building, King's Buildings, West Mains Road, Edinburgh, EH9 3JJ, UK

**Daniel Auriol** LIBRAGEN, 3 Rue des Satellites, 31400 Toulouse, France

**Manuela Avi** Lonza AG, CH-3930 Visp, Schweiz, Switzerland

**Kevin R. Bailey** Manchester Interdisciplinary Biocentre (MIB), University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK

**Neil Barnwell** AstraZeneca Global Process R&D, Bakewell Road, Loughborough, Leicestershire, UK

**Marco van den Berg** DSM Biotechnology Centre, Alexander Fleminglaan 1, 2613AX Delft, The Netherlands

**Maira L. Bode** CSIR Biosciences, PO Box 365, Pretoria 0001, South Africa

**Alessandra Bonamore** Dipartimento di Scienze Biochimiche, Sapienza University, Rome, Italy; and MOLIROM s.r.l, Rome, Italy

**Uwe T. Bornscheuer** Department of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, Greifswald University, Felix-Hausdorff-Str. 4, 17487 Greifswald, Germany

**Dean Brady** CSIR Biosciences, PO Box 365, Pretoria 0001, South Africa

**Eva Branda** Department of Applied Biology and Industrial Yeasts Collection DBVPG, Borgo XX Giugno 74, University of Perugia, 06121 Perugia, Italy

**Christoph Brandenbusch** Laboratory of Chemical Biotechnology, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Str. 66, 44227 Dortmund, Germany

**Cecilia Branneby** Cambrex Karlskoga AB, Sweden

**Gary Breen** GlaxoSmithKline, 1 Pioneer Sector 1, Singapore 628413

**Elisabetta Brenna** Dipartimento di Chimica, Materiali e Ingegneria Chimica "G. Natta", Politecnico di Milano, Via Mancinelli 7, 20131 Milano, Italy

**Maria S. Brown** Biocatalysis Center of Emphasis, Chemical R&D, Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Pfizer, Groton, Connecticut, USA

**Małgorzata Brzezińska-Rodak** Wrocław University of Technology, Faculty of Chemistry, Department of Bioorganic Chemistry, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland

**Bruno Bühler** Laboratory of Chemical Biotechnology, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Str. 66, 44227 Dortmund, Germany

**Colin M. Burns** Pfizer Worldwide Research and Development, Department of Chemical Research and Development, Ramsgate Road, Kent, CT13 9NJ, UK

**Michael P. Burns** Biocatalysis Center of Emphasis, Chemical R&D, Pharmaceutical Sciences, Pfizer Worldwide

Research and Development, Pfizer, Groton, Connecticut, USA

**Pietro Buzzini** Department of Applied Biology and Industrial Yeasts Collection DBVPG, Borgo XX Giugno 74, University of Perugia, 06121 Perugia, Italy

**Jian-Feng Cai** School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715, P. R. China

**John Carey** Reckitt Benckiser Pharmaceuticals, Dansom Lane, Hull, HU8 7DS, UK

**Elisa Caselli** Department of Chemistry, University of Modena and Reggio Emilia, via Campi 183, 41125 Modena, Italy

**Jim Cawley** Biocatalysis Center of Emphasis-CRD, Pharmaceutical Sciences, Pfizer Worldwide Research and Development, Pfizer, Groton, Connecticut, USA

**An Cerdobbel** Centre for Industrial Biotechnology and Biocatalysis, Faculty of Bioscience Engineering, Ghent University, Belgium

**Minho Cha** School of Chemical and Biological Engineering, SNU, Seoul, Republic of Korea; and School of Biotechnology, Yeungnam University, Gyeongsan, Gyeongbuk, Republic of Korea

**Anju Chadha** Laboratory of Bioorganic Chemistry, Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600036, India; and National Center for Catalysis Research, Indian Institute of Technology Madras, Chennai 600036, India

**Radka Chaloupkova** Loschmidt Laboratories, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, Masaryk University, Brno, Czech Republic; and Enantis Ltd, Brno, Czech Republic

**Graham Checksfield** Pfizer Worldwide Research and Development, Department of Chemical Research and Development, Ramsgate Road, Kent, CT13 9NJ, UK

**Jonathan Collins** Laboratory of Chemical Biotechnology, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Str. 66, 44227 Dortmund, Germany

**Andrew J. Collis** GlaxoSmithKline, Biological and Environmental Shared Service, North Lonsdale Road, Ulverston, Cumbria LA12 9DR, UK

**Maria Rita Cramarossa** Department of Chemistry, University of Modena and Reggio Emilia, via Campi 183, 41125 Modena, Italy

**Jiri Damborsky** Loschmidt Laboratories, Department of Experimental Biology and Research Centre for Toxic Compounds in the Environment, Masaryk University, Brno, Czech Republic; and Centre of Biomolecular and Cellular Engineering, International Clinical Research Centre, St. Anne's University Hospital Brno, Czech Republic; and Enantis Ltd, Brno, Czech Republic

**Shuvendu Das** Center for Biocatalysis and Bioprocessing, 2501 Crosspark Road, MTF-Suite C100, The University of Iowa, Coralville, IA 52241-3486, USA

**Daniela De Biase** Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Scienze e Biotechnologie Medico-Chirurgiche, Sapienza Università di Roma, Italy

**Pablo Domínguez de María** Institute of Technical and Macromolecular Chemistry (ITMC), RWTH Aachen University, Worringerweg 1. 52074 Aachen, Germany

**Karel De Winter** Centre for Industrial Biotechnology and Biocatalysis, Faculty of Bioscience Engineering, Ghent University, Belgium

**Tom Desmet** Centre for Industrial Biotechnology and Biocatalysis, Faculty of Bioscience Engineering, Ghent University, Belgium

**Mark Dow** School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK

**Bruno Dumas** Sanofi, SCP-Biologics, 13 quai Jules Guesde, 94400 Vitry sur Seine, France

**Thomas Eckrich** Chemical Product Research and Development, Eli Lilly and Company, Lilly Corporate Center, Drop 4813 Indianapolis, IN 46285, US

**Peter Eddowes** C-Tech Innovation Ltd, Capenhurst Technology Park, Chester CH1 6EH, UK

**Franck Escalettes** Manchester Interdisciplinary Biocentre, University of Manchester, Manchester, UK

**Kurt Faber** Department of Chemistry, Organic and Bioorganic Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria

**Ben L. Feringa** Center for Systems Chemistry, Stratingh Institute for Chemistry, University of Groningen, Nijenborgh 4, 9747 AG, Groningen, The Netherlands

**Luca Forti** Department of Chemistry, University of Modena and Reggio Emilia, via Campi 183, 41125 Modena, Italy

**Ian Fotheringham** Ingenza Limited, Joseph Black Building, King's Buildings, West Mains Road, Edinburgh, EH9 3JJ, UK

**Maurice C. R. Franssen** Laboratory of Organic Chemistry, Wageningen University, The Netherlands

**Andreas Fredenhagen** GDC/PSB/Separations, NIBR, Novartis Pharma AG, 4002 Basel, Switzerland

**Christine S. Fuchs** Department of Chemistry, Organic and Bioorganic Chemistry, University of Graz, Heinrichstrasse 28, 8010 Graz, Austria